Uptake of bone-modifying agents in patients with HER2 metastatic breast cancer with bone metastases – prospective data from a multi-site Australian registry

V Wong; R de Boer; C Dunn; A Anton; L Malik; S Greenberg; B Yeo; L Nott; IM Collins; J Torres; F Barnett; M Nottage; P Gibbs; SW Lok

Journal article

Uptake of bone-modifying agents in patients with HER2 metastatic breast cancer with bone metastases – prospective data from a multi-site Australian registry

V Wong, R de Boer, C Dunn, A Anton, L Malik, S Greenberg, B Yeo, L Nott, IM Collins, J Torres, F Barnett, M Nottage, P Gibbs, SW Lok

Internal Medicine Journal | WILEY | Published : 2022

DOI: 10.1111/imj.15376

Download PDF

Abstract

Background: International practice guidelines recommend administration of bone-modifying agents (BMA) in metastatic breast cancer (MBC) patients with bone metastases to reduce skeletal-related events (SRE). Optimal delivery of BMA in routine clinical practice, including agent selection and prescribing intervals, remains unclear. Aim: To describe real-world practice of Australian breast oncologists. Methods: Prospective data from February 2015 to July 2020 on BMA delivery to MBC patients with bone metastases was analysed from Treatment of Advanced Breast Cancer in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Australian Patient (TABITHA), a multi-site Australian HER2+ MBC regis..

View full abstract